We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi (SNY) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Sanofi (SNY - Free Report) closed the most recent trading day at $48.56, moving +1.17% from the previous trading session. The stock lagged the S&P 500's daily gain of 1.3%. At the same time, the Dow added 0.98%, and the tech-heavy Nasdaq gained 7.48%.
Prior to today's trading, shares of the drugmaker had gained 0.69% over the past month. This has outpaced the Medical sector's loss of 3.29% and the S&P 500's loss of 2.95% in that time.
Investors will be hoping for strength from Sanofi as it approaches its next earnings release. The company is expected to report EPS of $1.10, up 0.92% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $11.27 billion, up 3.85% from the year-ago period.
SNY's full-year Zacks Consensus Estimates are calling for earnings of $4.40 per share and revenue of $48.91 billion. These results would represent year-over-year changes of +1.15% and +8.3%, respectively.
It is also important to note the recent changes to analyst estimates for Sanofi. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Sanofi currently has a Zacks Rank of #3 (Hold).
Investors should also note Sanofi's current valuation metrics, including its Forward P/E ratio of 10.9. For comparison, its industry has an average Forward P/E of 13.89, which means Sanofi is trading at a discount to the group.
We can also see that SNY currently has a PEG ratio of 1.47. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.62 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 156, which puts it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sanofi (SNY) Gains But Lags Market: What You Should Know
Sanofi (SNY - Free Report) closed the most recent trading day at $48.56, moving +1.17% from the previous trading session. The stock lagged the S&P 500's daily gain of 1.3%. At the same time, the Dow added 0.98%, and the tech-heavy Nasdaq gained 7.48%.
Prior to today's trading, shares of the drugmaker had gained 0.69% over the past month. This has outpaced the Medical sector's loss of 3.29% and the S&P 500's loss of 2.95% in that time.
Investors will be hoping for strength from Sanofi as it approaches its next earnings release. The company is expected to report EPS of $1.10, up 0.92% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $11.27 billion, up 3.85% from the year-ago period.
SNY's full-year Zacks Consensus Estimates are calling for earnings of $4.40 per share and revenue of $48.91 billion. These results would represent year-over-year changes of +1.15% and +8.3%, respectively.
It is also important to note the recent changes to analyst estimates for Sanofi. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Sanofi currently has a Zacks Rank of #3 (Hold).
Investors should also note Sanofi's current valuation metrics, including its Forward P/E ratio of 10.9. For comparison, its industry has an average Forward P/E of 13.89, which means Sanofi is trading at a discount to the group.
We can also see that SNY currently has a PEG ratio of 1.47. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.62 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 156, which puts it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.